Years before the Oncology Care Model (OCM) was implemented, Northwest Medical Specialties started preparing by making changes to the personnel in the practice, explained Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
Years before the Oncology Care Model (OCM) was implemented, Northwest Medical Specialties started preparing by making changes to the personnel in the practice, explained Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.
Transcript
As Northwest Medical Specialties has participated in the Oncology Care Model, what were the most important changes to how you deliver care?
Well, we had to prepare for the Oncology Care Model implementation and it took us a few years before starting OCM, and we had to go through a lot of changes in the practice. Everybody calls it, as you know, practice transformation. Some of the major changes were creating the personnel and the support system that we didn’t have before, including patient care coordinators, case managers, clinical nurse specialists, and we did have social workers, but we redesigned the whole program and they created a big value-based care team that worked together to provide seamless care.
We also had to educate the whole organization, anybody who touched patient care. The receptionist to research nurse to the providers and there was a lot of repeated education to make people understand that we’re going to provide the care in a different way, and that is going to affect their day-to-day workload, and it caused a lot of intense changes for some people’s parts—especially providers. And the technology did cause a lot of stress because we had to use OncoEMR, our electronic health record, in a way that we didn’t use it before. So, yes there were a lot of changes before and during the OCM.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Insurance Gaps Threaten Cancer Treatment Success
July 7th 2025Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
Read More